Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Acquisition expands Merck’s growing hematology portfolio
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
